



APASL Oncology 2026 Tokyo

“Treatment Dynamics of Liver Tumors”

Scientific Program

APASL Oncology 2026 Tokyo Scientific Program

DAY 1, April 2 (Thursday) 2026

Room 1 “Ito Hall” B2F

9:00-9:10 **Opening Ceremony**

Opening Remarks: Dr. Shuntaro Obi, President of APASL Oncology 2026 Tokyo

9:10-10:40 **Session 1**

“Current Management of Intrahepatic & Hilar CCA (I/H-CCA): Combined Treatment Strategies of Biliary Drainage and Anti-Cancer Therapy”

Moderators: Dr. Jae Hee Cho (Korea), Dr. Hiroyuki Isayama (Japan), Dr. Hirofumi Kogure (Japan)

S1-1 Biliary Drainage and Anti-tumor Therapy for I/H-CCA: Real-World Sequencing in Asia

Dr. Jae Hee Cho (Korea)

S1-2 Endoscopic Management of Biliary Obstruction in I/H-CCA

Dr. Hirofumi Kogure (Japan)

S1-3 IO-Based Chemotherapy and Matched Therapy in I/H-CCA: What’s New and When to Start?

Dr. Takashi Sasaki (Japan)

S1-4 Consideration of Treatment Dynamics of I/H CCA from Tokyo Criteria

Dr. Hiroyuki Isayama (Japan)

S1-5 Molecular Basis of Intrahepatic Cholangiocarcinogenesis and Its Therapeutic Implications

Dr. Hiroaki Fujiwara (Japan)

S1-6 Landscape of the Biliary Cancer-Field Elucidated by Minute Dissection-Based Molecular Mapping: Opening A New Path to Early Diagnosis

Dr. Yusuke Kouchi (Japan)

Discussion: Integrating Drainage, Pathology, and Systemic Therapy - What Is the Optimal Sequence?

10:40-11:00 **Coffee Break**

11:00-11:45 **Session 2**

“Beyond irAEs: When Hepatic Toxicity Signals Therapeutic Success?”

Moderators: Dr. Tatsuo Kanda (Japan), Dr. Sadahisa Ogasawara (Japan), Dr. Tomoharu Yamada (Japan)

S2-1 Beyond the Storm: Life After irAEs - The Hepatic Frontier

Dr. Sadahisa Ogasawara (Japan)

S2-2 Hepatic irAEs and Survival Benefit: What We Learned from 924 Patients

Dr. Tatsuo Kanda (Japan)

S2-3 Innovative Bridging Therapies for HCC: From Transarterial Chemoembolization to Immune Checkpoint Inhibitors

Dr. Tomoharu Yamada (Japan)

Discussion: irAE=Favorable Prognostic Marker or Selection Bias?

12:00-13:00 Luncheon Seminar 1 (AbbVie GK)

“Accelerating Treatment Dynamics: Pan-Genotypic DAA and Beyond”

Moderator: Dr. Naoki Morimoto (Japan)

LS1-1 Hepatocellular Carcinoma and Remaining Clinical Issues in the HCV Eradication Era

Dr. Atsushi Hiraoka (Japan)

LS1-2 Treatment, Retreatment, and Post-Treatment Challenges of Maviret for HCV

Dr. Nobuharu Tamaki (Japan)

13:10-13:30 Keynote Lecture 1

“APASL and APASL ONCOLOGY”

Moderator: Dr. Shuntaro Obi (Japan)

Speaker: Dr. Masao Omata (Japan)

13:30-14:35 Session 3

“Biliary Drainage Before Chemotherapy: ERCP vs EUS-BD/A - The Gateway to Successful Treatment for I/H CCA”

Moderators: Dr. Rungsun Rerknimitr (Thailand), Dr. Yousuke Nakai (Japan), Dr. Naoki Sasahira (Japan)

S3-1 Video Lecture 1: Step-by-step ERCP for Malignant Biliary Obstruction before Chemotherapy

Dr. Rungsun Rerknimitr (Thailand)

S3-2 Video Lecture 2: EUS-guided Biliary Drainage/Anastomosis: Technical Pearls and Pitfalls
Dr. Sabro Matsubara (Japan)

S3-3 Does Quality of Biliary Drainage Affect Safety and Efficacy of Chemotherapy?
Dr. Yousuke Nakai (Japan)

S3-4 ERCP vs. EUS-BD/A ~Which should be the First-line Drainage? (Pro-ERCP)
Dr. Suguru Mizuno (Japan)

S3-5 Which should be the First-line Drainage? Pro-EUS
Dr. Kazuo Hara (Japan)

Discussion

14:35-14:50 **Coffee Break**

14:50-15:55 **Session 4**

“MASLD-Related HCC: From Risk Identification to Pharmacologic Prevention -Integrating Pathophysiology, Screening, and Intervention for the Next Era of HCC Prevention-”

Moderators: Dr. Yujin Hoshida (USA), Dr. Diana A. Payawal (Philippines), Dr. Takumi Kawaguchi (Japan)

S4-1 Epidemiologic Trends and Risk Factors for MASLD-related HCC in Asia
Dr. Diana A. Payawal (Philippines)

S4-2 Synergistic AI Approaches for Precision HCC Risk Stratification in MASLD: From Digital Pathology to Clinical Trajectory Prediction
Dr. Takuma Nakatsuka (Japan)

S4-3 Fibrosis, Stiffness Dynamics, and Cancer Risk: Lessons from MASLD Clinical Practice
Dr. Taeang Arai (Japan)

S4-4 Molecular Mechanisms of MASLD-related Hepatocarcinogenesis and Therapeutic Interception
Dr. Hayato Nakagawa (Japan)

S4-5 Pharmacologic Prevention of MASLD-related HCC: From SGLT2 Inhibitors to Next-Generation Metabolic Modulators
Dr. Takumi Kawaguchi (Japan)

Panel Discussion: “Integrating Translational Insights into Clinical Prevention”

15:55-16:15 **Special Session**

“From Idea to Impact: How Young Hepatologists Build Clinical Research Careers - Launching the APASL-Oncology School: Educating the Next Leaders in Liver Cancer Research –”

Moderator: Dr. Shuntaro Obi (Japan)

SS-1 From Clinical Questions to Practice-Changing Evidence: Educating the Next Leaders in Liver Cancer Research in Asia-Pacific

Dr. Ryosuke Tateishi (Japan)

SS-2 Competing on the Global Stage: Strategies for Young Investigators in Hepatology

Dr. Yujin Hoshida (USA)

16:15-16:55 **Keynote Lecture 2**

“Medication for Prevention and Treatment”

Moderator: Dr. Masao Omata (Japan)

KL2-1 FGF21 Analogs in MASLD/MASH: From Metabolic Remodeling to Fibrosis Reversal and HCC Risk Modification

Dr. Motoyuki Otsuka (Japan)

KL2-2 Anti-cancer Medication on Horizon: Genomic Profiling and Immunotherapy Integration

Dr. Shigehisa Kitano (Japan)

17:00-18:00 **Evening Seminar (Gilead Sciences K.K.)**

Moderator: Dr. Masao Omata (Japan)

ES Twilight of HCV-Related HCC: A Decade of Interferon-Free Revolution in Japan

Dr. Takahiro Kodama (Japan)

Panel Discussion: Can Japan’s Model Inform Global HCV Elimination?

18:00-19:00 **Poster Sessions at “Gallery 1&2” B1F, and “Event Space” B2F**

19:00-20:30 **Welcome Reception at “Event Space” B2F**

APASL Oncology 2026 Tokyo Scientific Program

DAY 1, April 2 (Thursday) 2026

Room 2 “Seminar Room” 3F

9:10-10:00 **Oral Free Paper Session 1**

Moderators: Dr. Yoshinari Asaoka (Japan), Dr. Takeshi Hatanaka (Japan)

FPS1-1 10053

Implementing Community-Based Hepatitis B Screening and Hepatocellular Carcinoma Screening in Resource-Limited Settings: A Qualitative Evaluation of Thailand's EZ Liver Network

Dr. Passakorn Wanchaijiraboon (Thailand)

FPS1-2 10223

A Large-Center Comparison of Hepatocellular Carcinoma Characteristics in Hepatitis C Patients Treated with Direct-Acting Antivirals Versus Untreated Patients

Dr. Mohamed Abdel-Samiee (Egypt)

FPS1-3 10107

Reduced Performance of Alpha-fetoprotein in Sustained Virological Response-related and Non-viral Early Hepatocellular Carcinoma: Complementary Value of PIVKA-II

Dr. Yuji Ikeda (Japan)

FPS1-4 10131

Clinical Characteristics and Surveillance Impact on Non-Viral Hepatocellular Carcinoma: A 20-Year Observational Study

Dr. Katsuya Nagaoka (Japan)

FPS1-5 10118

Integrative Clinical and Molecular Risk Score for Prevention of HBV-related HCC

Dr. Hiroyuki Suzuki (USA)

FPS1-6 10120

Serum Biomarker-based Score to Evaluate HCC Risk in HCV-cured Patients

Dr. Hiroaki Kanzaki (USA)

10:00-10:40 **Oral Free Paper Session 2**

Moderators: Dr. Kaoru Tsuchiya (Japan), Dr. Tomoharu Yamada (Japan)

FPS2-1 10123

Hepatocellular Carcinoma Stage, Treatment Patterns, and Survival Outcomes in a Contemporary Multicentre International Cohort

Dr. Yin Min Hwang (Singapore)

FPS2-2 10091

Development and Validation of a Deep Learning Model to Prognosticate Hepatocellular Carcinoma

Dr. Juequn Zhou (Singapore)

FPS2-3 10122

Young Onset Hepatocellular Carcinoma Presents at Advanced Stage with Limited Treatment Options

Dr. Amruthavarshini Nagabhushana (India)

FPS2-4 10136

Environmental Exposure to Cadmium, Lead, and Mercury as a Public Health Risk Factor for Hepatocellular Carcinoma

Dr. Ankush Kumar (India)

FPS2-5 10151

Feasibility and Safety of Hepatic Rehabilitation in HCC Patients with Decompensated Cirrhosis

Dr. Takumi Kawaguchi (Japan)

11:00-11:50 **Oral Free Paper Session 3**

Moderators: Dr. Takashi Sasaki (Japan), Dr. Natsuyo Yamamoto (Japan)

FPS3-1 10011

Aging-Driven Immunosuppressive Remodeling of the Tumor Microenvironment in Gallbladder Cancer: Insights from Single-Cell Transcriptomics

Dr. Lei Kong (China)

FPS3-2 10144

KLF5 Mediates a Galectin1-FBP1-RAS/ERK Cascade to Drive Proliferation and Migration in Intrahepatic Cholangiocarcinoma

Dr. Xing Yu (China)

FPS3-3 10167

**Lactylation of PPP1CA at K305 Promotes Lymph Node Metastasis in Intrahepatic
Cholangiocarcinoma by Sustaining TGF- β Signaling**

Dr. Yuheng Hu (China)

FPS3-4 10202

**Epigenetic Silencing of PTEN as a Prognostic and Translational Biomarker in Periampullary
Adenocarcinoma**

Dr. Asgar Ali (India)

FPS3-5 10184

**Prognostic Impact of Adipose Tissue Volume in Unresectable Biliary Tract Cancer Treated with
Gemcitabine, Cisplatin, and Immunotherapy**

Dr. Tsuyoshi Takeda (Japan)

FPS3-6 10172

Feasibility and Safety of Endoscopic Ultrasound-guided Tissue Acquisition for Biliary Lesions

Dr. Keito Nakagawa (Japan)

12:00-13:00 Luncheon Seminar 2 (Eisai Co., Ltd.)

“Future Multidisciplinary Treatment Strategies Based on Therapeutic Goals and Tumor Status”

Moderator: Dr. Masafumi Ikeda (Japan)

**LS2-1 Deepening and Advancing Multidisciplinary Treatment for Hepatocellular Carcinoma:
Tumor Status-Based Approaches Combining Lenvatinib and Interventional Radiology**

Dr. Nobuhito Taniki (Japan)

**LS2-2 Optimizing Drug Sequencing and Integrated Strategies in Hepatocellular Carcinoma:
Maximizing the Therapeutic Potential of Lenvatinib in the ICI Era**

Dr. Teiji Kuzuya (Japan)

13:30-14:02 Late Breaker Session 1

Moderators: Dr. Hideaki Ijichi (Japan), Dr. Ryota Masuzaki (Japan)

LBS1-1 10248

**HLA-DR⁺ Tumor Cells Mimic Antigen-presenting Cells to Mediate Immunosuppression in HBV-
related Hepatocellular Carcinoma**

Dr. Wenjing Yuan (China)

LBS1-2 10236

High Ammonia Promotes EHHADH-dependent Pyrimidine Degradation to Induce Inflammatory Cell Death in HCC

Dr. Jinhui Wei (China)

LBS1-3 10239

Sarcomatoid Transformation is Associated with Immunosuppressive Remodeling in Hepatocellular Carcinoma

Dr. Ryo Morisue (Japan)

LBS1-4 10254

Bile-based Liquid Biopsy for Diagnosis and Therapeutic Stratification of Biliary Strictures

Dr. Hiroshi Ohyama (Japan)

14:02-14:35 Late Breaker Session 2

Moderators: Dr. Yoshihiro Hirata (Japan), Dr. Hideo Yoshida (Japan)

LBS2-1 10246

Large Language Models Underperform Multidisciplinary Teams for Hepatocellular Carcinoma Treatment Decisions Despite Escalating Prompting Strategies: A Prospective Study

Dr. Amith Vishwanath (India)

LBS2-2 10272

Causal Machine Learning-Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma

Dr. Jun-Hao Mei (China)

LBS2-3 10232

NEO-ERA-01: A phase II Study of Neoadjuvant HAIC (GEMOX) Plus Adebrelimab and Lenvatinib in High-risk Resectable Intrahepatic Cholangiocarcinoma

Dr. Jianhua Rao (China)

LBS2-4 10250

Stage-dependent Liver Stiffness Resolution after HCV SVR: a Longitudinal 8-year Follow-up Study

Dr. Shuntaro Obi (Japan)

14:50-15:06 Late Breaker Session 3

Moderators: Dr. Yoshihiro Hirata (Japan), Dr. Hideo Yoshida (Japan)

LBS3-1 10241

Efficacy and Safety of Postoperative Adjuvant Donafenib Therapy in Patients with High-risk Recurrence after Radical Resection of Hepatocellular Carcinoma: A Multicenter Retrospective Study

Dr. Jianhua Rao (China)

LBS3-2 10273

The Risk of Decompensation in Steatotic Liver Disease-related Hepatocellular Carcinoma after Curative Treatment

Dr. Yuki Matsushita (Japan)

14:50-15:30 Oral Free Paper Session 4

Moderators: Dr. Kazuya Okushin (Japan), Dr. Yasuo Tanaka (Japan),

FPS4-1 10094

MicroRNA-199a-5p Disrupts Unfolded Protein Response-mediated Stress Adaptation in Hepatocellular Carcinoma Cells

Dr. Chaiyaboot Ariyachet (Thailand)

FPS4-2 10108

Dynamic Regulation of Membrane Fluidity Drives Tumor Evolution and Attenuates TNF α-Mediated Apoptosis in Hepatocellular Carcinoma

Dr. Boqiang Liu (China)

FPS4-3 10162

AARS1 Promotes Tumor Progression and Immune Evasion through ATF6 Lactylation-driven Tryptophan Metabolism in Hepatocellular Carcinoma

Dr. Yiming Wang (China)

FPS4-4 10178

Dfna5-dependent Hepatocyte Death Promotes Inflammatory TNF Signaling in Kupffer Cells to Drive Hepatocarcinogenesis

Dr. Tomoya Hamabe (Japan)

15:30-16:00 Oral Free Paper Session 5

Moderators: Dr. Jun Arai (Japan), Dr. Naoki Morimoto (Japan)

FPS5-1 10100

Natural Killer Cell Drives Liver Cancer Evolution Through Cholesterol Metabolism Reprogramming

Dr. Liang Shi (China)

FPS5-2 10147

A Fe-Curcumin-based Strategy to Reinvigorate CAR-T Cells by Reversing Exhaustion and Senescence in Liver Cancer

Dr. Yuchan Xue (China)

FPS5-3 10119

Reverse-engineering Strategy Identified DDR1 as HCC Chemoprevention Target Post HCV Cure

Dr. Hiroaki Kanzaki (USA)

APASL Oncology 2026 Tokyo Scientific Program

DAY 2, April 3 (Friday) 2026

Room 1 “Ito Hall” B2F

9:00-10:30 **Session 5**

“Systemic Therapy for HCC: Asia-Pacific Treatment Dynamics”

Moderators: Dr. Yi-Hsiang Huang (Taiwan), Dr. Masatoshi Kudo (Japan), Dr. Ryosuke Tateishi (Japan)

S5-1 How Do We Decide the Best First-line Therapy?

Dr. George Lau (Hong Kong SAR, China)

S5-2 Mainland China Perspective: Access, Sequence, and New Combination Strategies

Dr. Lai Wei (China)

S5-3 Taiwan Experience: Balancing TKI, ICI, and Real-world Constraints

Dr. Yi-Hsiang Huang (Taiwan)

S5-4 Systemic Therapy for Advanced Hepatocellular Carcinoma in the Era of Combination Immunotherapy: Real-world Treatment Sequences and Outcomes from the HERITAGE Study

Dr. Yoshinari Asaoka (Japan)

S5-5 How Do We Sequence Systemic Therapy in Daily Practice?

Dr. Sadahisa Ogasawara (Japan)

S5-6 Systemic Therapy Biomarkers: Translating Molecular Signatures into Clinical Decisions

Dr. Takahiro Kodama (Japan)

S5-7 The Evolving Landscape of Systemic Therapy

Dr. Ryosuke Tateishi (Japan)

Discussion

10:30-10:45 **Coffee Break**

10:45-11:50 **Session 6**

“Surgical Resectability and Liver Transplantation for HCC: Redefining the Boundaries Across Asia”

Moderators: Dr. Itsuko Chih-Yi Chen (Taiwan), Dr. Etsuro Hatano (Japan), Dr. Kiyoshi Hasegawa (Japan)

S6-1 The Experience of Liver Transplantation for HCC in Qingdao

Dr. Cai Jinzhen (China)

S6-2 Optimizing Outcomes of Living Donor Liver Transplantation for Hepatocellular Carcinoma

Dr. Itsuko Chih-Yi Chen (Taiwan)

S6-3 How We Define Resectability of HCC in Practice

Dr. Junichi Shindo (Japan)

S6-4 The Concept of Borderline Resectable HCC: Japanese Perspective

Dr. Etsuro Hatano (Japan)

Discussion

12:00-13:00 Luncheon Seminar 3 (Chugai Pharmaceutical Co., Ltd.)

“Five-Year Experience of Atezolizumab plus Bevacizumab for HCC: Clinical Insights and Future Strategies”

Moderator: Dr. Masafumi Ikeda (Japan)

LS3-1 Optimizing Atezolizumab-Bevacizumab Therapy for HCC: Real-World Evidence from 5-Year Multicenter Analysis of 1,200 Cases

Dr. Joji Tani (Japan)

LS3-2 How to Optimize Atezolizumab plus Bevacizumab for Real-World HCC: Sequencing, Early Biomarkers, and On-Demand Add-On TACE

Dr. Teiji Kuzuya (Japan)

13:10-13:30 Keynote Lecture 3

“Overwhelming Number of HCC Cases with Portal Hypertension: Address a Big Challenge”

Moderators: Dr. Masao Omata (Japan), Dr. Shuntaro Obi (Japan)

Speaker: Dr. Shiv K Sarin (India)

13:30-14:45 Session 7

“A-HOC Rising: Advancing Hepatocellular Carcinoma Care through Regional Collaboration”

Moderators: Dr. Amarsanaa Jazag (Mongolia), Dr. Motoyuki Otsuka (Japan), Dr. Ryousuke Tateishi (Japan)

S7-1 What is A-HOC? Consortium Vision, Structure, and Activities: APASL Oncology = Platform for A-HOC Expansion

Dr. Shuntaro Obi (Japan)

S7-2 Building a Unified HCC Dataset: Turkey's Contribution to A-HOC's Regional Evidence Platform

Dr. A. Kadir Dokmeci (Turkey)

S7-3 A-HOC Data: Creating New Research Opportunities for Young Investigators

Dr. Yasuto Takeuchi (Japan)

S7-4 Country Spotlight: HCC Practice and Data Needs in Mongolia

Dr. Amarsanaa Jazag (Mongolia)

S7-5 Uniting Islands, Uniting Data: Indonesia's Role in the A-HOC Network

Dr. Rino Gani (Indonesia)

S7-6 Empowering Regional Collaboration and Education: Thailand's Role in A-HOC

Dr. Teerha Piratvisuth (Thailand)

Discussion

Comment by Dr. Masao Omata (As founder)

14:45-15:00 **Coffee Break**

15:00-16:05 **Session 8**

"Image-Guided Interventions for HCC: Regional Practice, Education, and Future Directions"

Moderators: Dr. Kai-Wen Huang (Taiwan), Dr. Shuichiro Shiina (Japan), Dr. Toshihiro Tanaka (Japan)

S8-1 Dissemination and Education of RFA and MWA in the Asia-Pacific Region

Dr. Shuichiro Shiina (Japan)

S8-2 Local Ablation for HCC: Training and Skill Advancement in Taiwan

Dr. Kai-Wen Huang (Taiwan)

S8-3 ReMAP-Based Transarterial Embolization: Toward Personalized IVR

Dr. Toshihiro Tanaka (Japan)

S8-4 The Evolution of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Multidisciplinary Strategies in the Era of Chemo-diversity

Dr. Hideki Iwamoto (Japan)

S8-5 Heavy Ion Radiotherapy for HCC: A New Frontier in Interventional Oncology

Dr. Hirokazu Makishima (Japan)

Discussion

16:05-16:35 **Plenary Session**

Moderators: Dr. Yasuhito Tanaka (Japan), Dr. Keisuke Tateishi (Japan)

PS-1 10177

Plasma TWEAK as a Predictive Biomarker of Response to Tremelimumab plus Durvalumab in Advanced Hepatocellular Carcinoma

Dr. Takeru Hirao (Japan)

PS-2 10130

Surgical Benefit and Futility in Borderline Resectable Hepatocellular Carcinoma: A Multicenter Study

Dr. Norifumi Iseda (Japan)

PS-3 10003

The First Application and Feasibility Assessment of 5G-enabled Remote Robot-assisted Hepatobiliary and Pancreatic Surgery in Patients with Malignant Tumors

Dr. Xingru Wang (China)

16:35-16:50 **Awarding & Closing Ceremony**

APASL Oncology 2026 Tokyo Scientific Program

DAY 2, April 3 (Friday) 2026

Room 2 “Seminar Room” 3F

9:00-10:30 **Video Session**

Moderators: Dr. Hiroaki Nagano (Japan), Dr. Masayuki Otsuka (Japan)

VS-1 10073

Pitfalls in Posterior Sectionectomy and S7 Segmentectomy Focusing on the Running Pattern of the Right Posterior Inferior Portal Branch (P6a) and Portal Vein Branching Anatomy

Dr. Gakushi Kitamura (Japan)

VS-2 10074

Surgical Strategy for Laparoscopic Right Intersectional Plane Resection in Right Anterior/Posterior Sectionectomy and S7/S8 Segmentectomy, Based on the Courses of P6a and the Right Hepatic Vein

Dr. Yusuke Yamamoto (Japan)

VS-3 10004

Infrared Laser-guided Laparoscopic Portal Vein Drainage Area Anatomic Liver Resection Using ICG Positive Staining

Dr. Xingru Wang (China)

VS-4 10077

Optimizing Specimen Extraction in Laparoscopic Resection of Giant Liver Tumors Using a Pfannenstiel Incision

Dr. Rie Shibata (Japan)

VS-5 10143

Advanced Minimally Invasive Hepatectomy Through Standardized Hepatic Vein Control- Translating Laparoscopic Strategies to Robotic Surgery -

Dr. Taisuke Imamura (Japan)

VS-6 10069

Initial Experience with Robot-assisted Liver Resection Using the da Vinci SP System

Dr. Mei Nakamura (Japan)

VS-7 10090

EUS-Guided Portal Vein Sampling as a Novel Liquid Biopsy Approach for Pancreatic Cancer

Dr. Hiroki Yamana (Japan)

10:45-11:17 **Oral Free Paper Session 6**

Moderators: Dr. Toru Arano (Japan), Dr. Tatsuya Minami (Japan)

FPS6-1 10038

Clinical Characteristics of Combination Immunotherapy in Elderly Patients with Unresectable Hepatocellular Carcinoma

Dr. Chikako Nagao (Japan)

FPS6-2 10064

Prognostic Value of Combined Child– Pugh Score and Modified Albumin– Bilirubin Grade in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Dr. Tomonao Taira (Japan)

FPS6-3 10106

Association of Lenvatinib Pharmacokinetics with mALBI in Hepatocellular Carcinoma and Evaluation of Efficacy and Safety

Dr. Yumi Otoyama (Japa)

FPS6-4 10139

Regional Lymph Node Metastasis in Hepatocellular Carcinoma Treated with Immune-based Systemic Therapy: Prognostic Significance and Implications for Clinical Staging

Dr. Qian Chen (China)

11:17-11:50 **Oral Free Paper Session 7**

Moderators: Dr. Hiroaki Nagamatsu (Japan), Dr. Hiroyoshi Taniguchi (Japan)

FPS7-1 10097

Should Transarterial Chemoembolization Be Applied with Systemic Therapy for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus?: A Multicenter Study

Dr. Long-Wang Lin (China)

FPS7-2 10160

Real-World Outcomes of Sequential Transarterial Chemoembolization followed by Atezolizumab-Bevacizumab in Patients with Advanced Hepatocellular Carcinoma

Dr. Soe Thiha Maung (Thailand)

FPS7-3 10183

Efficacy of Combined Three-Dimensional Conformal Radiotherapy and Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion

Dr. Joji Tani (Japan)

13:30-13:55 Oral Free Paper Session 8

Moderators: Dr. Yoshikuni Kawaguchi (Japan), Dr. Keiji Sano (Japan)

FPS8-1 10111

Prognostic Impact of the Oncological Resectability Criteria in Patients Undergoing Liver Resection for Hepatocellular Carcinoma

Dr. Hayato Abe (Japan)

FPS8-2 10078

Surgical Outcomes and Treatment Strategies for Solitary Giant Hepatocellular Carcinoma

Dr. Atomu Suzuki (Japan)

FPS8-3 10146

Association between Prophylactic Antibiotics and Post-ablation Infections in Hepatocellular Carcinoma Patients: A Retrospective Multicenter Cohort Study

Dr. Ting Luo (China)

13:55-14:15 Oral Free Paper Session 9

Moderators: Dr. Yukihiro Koike (Japan), Dr. Ryota Masuzaki (Japan)

FPS9-1 10076

PIVKA-II Monitoring to Predict Response to the First Transarterial Chemoembolization (TACE) in Intermediate-Stage Hepatocellular Carcinoma

Dr. Chitchai Rattananukrom (Thailand)

FPS9-2 10158

Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Refractory Gastrointestinal Bleeding in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis: A Prospective Cohort Study

Dr. Atteyat Semeya (Saudi Arabia)

14:15-14:45 Oral Free Paper Session 10

Moderators: Dr. Takamasa Ohki (Japan), Dr. Toshihiro Tanaka (Japan)

FPS10-1 10029

Development of Novel Deep Multimodal Representation Learning-based Model for the Differentiation of Liver Tumors on B-Mode Ultrasound Images

Dr. Masaya Sato (Japan)

FPS10-2 10204

Dissociation Between Multiphasic CT-Defined Tumor Burden and Endoscopic Portal Hypertension Severity in Cirrhotic and Non-Cirrhotic Hepatocellular Carcinoma

Dr. Aldisa Puspitasari (Indonesia)

FPS10-3 10210

Stereotactic Body Radiotherapy Enhances the Efficacy of Nivolumab in Advanced Hepatocellular Carcinoma: A Comparative Cohort Analysis

Dr. Phool Chand (India)

15:00-15:32 Young Investigator Award Session 1

Moderators: Dr. Shin Maeda (Japan), Dr. Suguru Mizuno (Japan)

YIA1-1 10013

Repurposing Resmetirom Suppresses MASH-associated Hepatocellular Carcinoma, with Mechanistic Implications of MDK/LRP1-mediated Metabolic Reprogramming and Immunosuppression

Dr. Vanilla Xin Zhang (Hong Kong)

YIA1-2 10017

Transitional Hepatocytes and Immunosuppressive Macrophages Drive NASH-Associated Liver Cancer Revealed by Single-Cell Transcriptomics

Dr. Firdian Makrufardi (Indonesia)

YIA1-3 10047

Gemcitabine Modulates the Tumor Immune Microenvironment to Enhance Response to Immune-checkpoint Inhibitors in Biliary Tract Cancer

Dr. Kenji Nose (Japan)

YIA1-4 10065

Strategic Integration of Locoregional Interventions to Optimize Survival Outcomes following First-line ICI Combinations in Advanced Hepatocellular Carcinoma

Dr. Masaki Omori (Japan)

Moderators: Dr. Shin Maeda (Japan), Dr. Suguru Mizuno (Japan)

YIA2-1 10020

Impact of Antihypertensive Drug Selection on Proteinuria Risk During Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma

Dr. Takashi Kitagataya (Japan)

YIA2-2 10060

Pretreatment Serum Heparin-Binding Protein as a Predictive Biomarker for Atezolizumab Plus Bevacizumab Therapy in Advanced Hepatocellular Carcinoma

Dr. Satoshi Narahara (Japan)

YIA2-3 10041

Novel Risk Score Incorporating Type-IV Collagen, Albumin, and Prothrombin Time (CAP score) to Predict 180-Day Surgery-Related Mortality After Liver Resection for Hepatocellular Carcinoma

Dr. Tomoaki Hayakawa (Japan)

YIA2-4 10070

Unexpected Rapid Progression of Hepatocellular Carcinoma After Radiofrequency Ablation

Dr. Takuma Kaneko (Japan)

APASL Oncology 2026 Tokyo Poster Session Program

DAY 1, April 2 (Thursday) 2026

Poster Area “Gallery 1&2” B1F, “Event Space” B2F

18:00-19:00 **Poster Free Paper Sessions**

Poster Group 1 Biliary Poster Session 1

Moderator: Dr. Toshihiko Arizumi (Japan)

BP1-1 10182

Divergent Chromosomal Architectures in Cholangiocarcinoma Cell Lines with Comparable Proliferation Rates: Implications for Genomic Heterogeneity

Dr. Ratana Leksomboon (Thailand)

BP1-2 10148

The Impact and Mechanisms of YES1 in Intrahepatic Cholangiocarcinoma Progression

Dr. Tao Han (China)

BP1-3 10019

Clinicopathological Features of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Intrahepatic Cholangiocarcinoma

Dr. Zhaohui Tang (China)

BP1-4 10056

Prognostic Impact of Etiologies on Intrahepatic Cholangiocarcinoma: An Analysis of a Nationwide Registry

Dr. Kazuya Okushin (Japan)

BP1-5 10161

Dose-response Association between Waist Circumference and Risk of Cholangiocarcinoma: A Nationwide Population-based Cohort Study

Dr. Joo-Hyun Park (Korea)

Poster Group 2 Biliary Poster Session 2

Moderator: Dr. Nobuo Toda (Japan)

BP2-1 10141

Clinical Utility of Peroral Cholangioscopy-Guided Biopsy in the Diagnosis of Biliary Lesions

Dr. Nobuhiro Katuskura (Japan)

BP2-2 10063

Optimal Biliary Drainage for Malignant Hilar Biliary Obstruction

Dr. Naminatsu Takahara (Japan)

BP2-3 10089

Selective Endoscopic Nasobiliary Drainage to Determine the Resection Range for Intraductal Papillary Neoplasm of the Bile Duct with an Indeterminate Primary Site: A Case Report

Dr. Junichi Kaneko (Japan)

BP2-4 10133

Case Report of Primary Hepatic Carcinoma Complicated with Cholangiolar Sarcomatoid Carcinoma

Dr. Jiawei Zhang (China)

Poster Group 3 Biliary Poster Session 3

Moderator: Dr. Kenji Hirano (Japan)

BP3-1 10173

Advances in the Management of Intrahepatic Cholangiocarcinoma and Temporal Changes in Prognosis: A Prospective Long-Term Real-World Data Analysis

Dr. Sumio Hirose (Japan)

BP3-2 10127

Hepatic Arterial Infusion Chemotherapy with New FP (NFP) for Unresectable Intrahepatic Cholangiocarcinoma: A Single-Center Retrospective Study

Dr. Hiroto Ota (Japan)

BP3-3 10067

Analysis of Prognostic Factors for ICI Combination Regimens in Unresectable Biliary Tract Cancer

Dr. Mai Kitahara (Japan)

BP3-4 10187

Immune Checkpoint Inhibitors Combined with Chemotherapy and Comprehensive Genomic Profiling Test for Advanced Biliary Tract Cancer in Our Hospital

Dr. Morito Ikeda (Japan)

BP3-5 10209

The Impact of Antibiotics on ICI Combination Chemotherapy in Advanced Biliary Tract Cancer

Dr. Shota Iwahara (Japan)

BP3-6 10045

Two Cases of Unresectable Combined Hepatocellular-Cholangiocarcinoma Treated with Immune Checkpoint Inhibitors

Dr. Yasuhide Motoyoshi (Japan)

Poster Group 4 Basic & Experimental Poster Session 1

Moderator: Dr. Yotaro Kudo (Japan)

BEP1-1 10026

SLC12A2-driven Suppression of Hepatic Lipolysis Shapes a Tumor-promoting Microenvironment in Metabolically Steatotic Livers

Dr. Yotaro Kudo (Japan)

BEP1-2 10196

Accumulation of Autophagy-specific Substrate p62/SQSTM1 is Associated with Multinucleation in Human Hepatocellular Carcinoma

Dr. Shunhei Yamashita (Japan)

BEP1-3 10117

Investigation of the Anti-tumor and Anti-HBV Effects of the Host Factor FAH

Dr. Shouichi Namikawa (Japan)

BEP1-4 10134

Ameliorative Role of Phytosterol Pre-Treatment in N-Nitrosodiethylamine Induced Oxidative Stress in Female Albino Rats

Dr. Rahul Kumar (India)

Poster Group 5 Basic & Experimental Poster Session 2

Moderator: Dr. Yotaro Kudo (Japan)

BEP2-1 10022

Clinical Characteristics of Immune-hot Hepatocellular Carcinoma

Dr. Yuya Miura (Japan)

BEP2-2 10109

Multi-omics Profiling Reveals the Prognostic Features and Tumor Microenvironment of High-stemness HCC

Dr. Yu Luo (China)

BEP2-3 10145

ZIP1-CAF Shapes the Immunosuppressive Microenvironment to Drive Hepatocellular Carcinoma Progression

Dr. Jiangxi Liu (China)

BEP2-4 10132

Microenvironmental Analysis of Resistance to Atezo+Bev Therapy in Unresectable Hepatocellular Carcinoma: Involvement of High M2BP Expression and Inflammatory Cancer-Associated Fibroblasts

Dr. Katsuya Nagaoka (Japan)

BEP2-5 10176

Association of HAMP Expression and CD8+ T-cell Infiltration with Atezolizumab plus Bevacizumab Response in Hepatocellular Carcinoma

Dr. Shun Nakamura (Japan)

Poster Group 6 Basic & Experimental Poster Session 3

Moderator: Dr. Naoto Fujiwara (Japan)

BEP3-1 10192

Mutation Profiles of TERT, TP53, and CTNNB1 Genes from Circulating Cell Free DNA as Non-Invasive Prognostic Biomarkers in HBV-Induced Hepatocellular Carcinoma

Dr. Afzalun Nessa (Bangladesh)

BEP3-2 10201

Performance of Circulating 5-Hydroxymethylcytosine Epigenetic Signatures in Detecting Hepatocellular Carcinoma Among Patients with Cirrhosis

Dr. Rishabh Sharma (India)

BEP3-3 10010

Identification of Novel Prognostic Biomarkers and Molecular Pathogenesis Insights in Hepatocellular Carcinoma through Integrated Multi-Database Analysis

Dr. Md Shariful Islam (USA)

BEP3-4 10222

The VETC Associated Trabecular Subtypes in Non-cirrhotic HCC is Defined by Loss of Tumor Suppressor and Downregulation of Ribosomal Genes

Dr. Archana Rastogi (India)

BEP3-5 10197

Hepatocellular Carcinoma in Armenia: Primary Assessment of Molecular Alterations

Dr. Hasmik Ghazinyan (Armenia)

Poster Group 7 Basic & Experimental Poster Session 4

Moderator: Dr. Hironao Okubo (Japan)

BEP4-1 10154

Global Research Landscape and Thematic Evolution of Immune Cell Metabolic Reprogramming in Liver Disease and Hepatic Oncology: A Bibliometric and Science Mapping Analysis

Dr. Ziteng Wang (China)

BEP4-2 10066

The Relationship between the Expression of Tumor Microenvironment-related Genes and the Gene Mutations of Hepatocellular Carcinoma from TCGA Data

Dr. Yoshinari Asaoka (Japan)

BEP4-3 10021

Integrative Machine Learning and Experimental Validation Identify MYBL2 as a Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma

Dr. Ya-Ling Yang (Taiwan)

BEP4-4 10203

Clinical Significance of Serum VEGF Levels in Patients with Unresectable Hepatocellular Carcinoma Treated with Durvalumab plus Tremelimumab

Dr. Yutaka Yasui (Japan)

BEP4-5 10225

Impact of Hepatocyte Nuclear Factor-1 Alpha Genetic Variants on Hepatocellular Carcinoma Susceptibility among Patients with and without Diabetes Mellitus

Dr. Mohamed Abdel-Samiee (Egypt)

Poster Group 8 Hepatitis & Chronic Liver Disease Poster Session 1

Moderator: Dr. Tatsuo Kanda (Japan)

HCP1-1 10042

Risk Factors for Hepatocellular Carcinoma Development after Direct-acting Antiviral Therapy in Hepatitis C: A Long-term Follow-up Study

Dr. Rino Nakamura (Japan)

HCP1-2 10138

HCC Development in HCV-Infected Patients after Virological Response

Dr. Narina Sargsyants (Armenia)

HCP1-3 10027

**Early Detection of De Novo Hepatocellular Carcinoma by AFP-L3 Fraction Following SVR for HCV:
A Case Report**

Dr. Takahisa Sato (Japan)

HCP1-4 10081

**A Case of Hepatocellular Carcinoma with Decompensated Hepatitis C-related Liver Cirrhosis that
Achieved a Sustained Virological Response after Retreatment with Glecaprevir/Pibrentasvir**

Dr. Satoru Kakizaki (Japan)

HCP1-5 10115

**Ruptured Hepatocellular Carcinoma in an Untreated HCV Patient: Emergency Management, Viral
Eradication, and Aggressive Recurrence**

Dr. Kentaro Takahashi (Japan)

HCP2-1 10015

Hepatocellular Carcinoma in Japanese Autoimmune Hepatitis: Management and Outcomes

Dr. Tomoko Tadokoro (Japan)

Poster Group 9 Hepatitis & Chronic Liver Disease Poster Session 2

Moderator: Dr. Atsushi Tanaka (Japan)

HCP2-2 10049

A Study on Hepatocellular Carcinoma with Autoimmune Hepatitis as Background Liver Disease

Dr. Hideo Yoshida (Japan)

HCP2-3 10142

**Late-Onset Hepatic Failure (LOHF) Caused by Seronegative Acute-Onset Autoimmune Hepatitis
Requiring Liver Transplantation**

Dr. Keigo Misawa (Japan)

HCP2-4 10057

Validation of PBC-10 in Japanese Patients with Primary Biliary Cholangitis

Dr. Akihito Takeuchi (Japan)

HCP2-5 10025

Changes in Symptomatic Presentation at Diagnosis and Prognostic Impact in Primary Biliary Cholangitis

Dr. Akihito Takeuchi (Japan)

Poster Group 10 Hepatitis & Chronic Liver Disease Poster Session 3

Moderator: Dr. Kenichi Ikejima (Japan)

HCP3-1 10124

Aetiology-Specific Risk of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease

Dr. Yu Xi Tan (Singapore)

HCP3-2 10087

Characteristics of Hepatocellular Carcinoma Arising from Alcohol-associated Steatotic Liver Disease

Dr. Yuri Ogasawara (Japan)

HCP3-3 10185

Intermittent Fasting, Liver Fibrosis, and Hepatocellular Carcinoma Risk in Non-Alcoholic Fatty Liver Disease: A Scoping Review

Dr. Inas Karimi (Indonesia)

HCP3-4 10159

Sarcopenia in Cirrhotic Patients: Prevalence, Prognostic Impact, and Clinical Outcomes

Dr. Atteyat Semeya (Saudi Arabia)

HCP3-5 10075

Acid-Suppressing Therapy and the Risk of Hepatic Encephalopathy in Cirrhosis: A Prospective Cohort Study

Dr. Keiichi Katayama (Japan)

Poster Group 11 Hepatitis & Chronic Liver Disease Poster Session 4

Moderator: Dr. Amarsanaa Jazag (Mongolia)

HCP4-1 10174

Global Trends in Liver Cancer Attributable to Hepatitis B: Insights from the Global Burden of Disease 2023 Study

Dr. Ekram Hasanin (Libya)

HCP4-2 10125

Global Prevalence and Incidence of Primary Sclerosing Cholangitis: An Updated Meta-Analysis

Dr. Asvin Selvakumar (Singapore)

HCP4-3 10126

Genome-wide Association Study of TG/HDL Ratio in 424,865 UK Biobank Participants

Dr. Jordan Low (Singapore)

HCP4-4 10208

Treatment Outcomes of Triple Therapy for 816 NAFLD Patients in Mongolia

Dr. Amarsanaa Jazag (Mongolia)

Poster Group 12 Hepatitis & Chronic Liver Disease Poster Session 5

Moderator: Dr. Tatsuya Minami (Japan)

HCP5-2 10199

Hepatoprotective Drugs for the Prevention of Liver Injury among Patients at Risk for Drug-Induced Liver Injury or Chemotherapy-Induced Transaminitis: A Systematic Review and Meta-Analysis

Dr. Cheryl J. Toledano (Philippines)

HCP5-3 10163

Five-year Active Surveillance of Unresectable Hepatic Epithelioid Hemangioendothelioma Diagnosed by Repeat Liver Biopsy

Dr. Noriyo Yamashiki (Japan)

HCP5-4 10121

Efficacy of a Novel Ultra Slim Therapeutic Upper Gastrointestinal Endoscope for Pediatric Esophageal Varices A Case Report

Dr. Ryosuke Kawanishi (Japan)

Poster Group 13 Hepatitis & Chronic Liver Disease Poster Session 6

Moderator: Dr. Masaya Sato (Japan)

HCP6-1 10216

Steep Declining Trends of Hepatitis Virus Prevalence in Mongolia over the last 20 years, a Nationwide Study

Dr. Amarsanaa Jazag (Mongolia)

HCP6-2 10219

Routes of New Viral Hepatitis Infections in Modern Mongolia

Dr. Amarsanaa Jazag (Mongolia)

HCP6-3 10212

Alcohol Consumption and Its Association with HCC in Mongolia according to A-HOC Study

Dr. Amarsanaa Jazag (Mongolia)

HCP6-4 10220

Association of HbA1c with Liver Steatosis and Fibrosis in Mongolia

Dr. Amarsanaa Jazag (Mongolia)

HCP6-5 10058

Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights from a Decade of Follow-Up

Dr. Akihito Takeuchi (Japan)

Poster Group 14 HCC Poster Session 1

Moderator: Dr. Shinpei Sato (Japan)

HP1-1 10191

A-HOC (APASL Hepatology/Oncology Consortium): A Foundational Dataset for Future Hepatology and Oncology Research

Dr. Hitoshi Mochizuki (Japan)

HP1-2 10205

A-HOC Study on 1108 Patients Under Surveillance for Liver Cancer in Mongolia

Dr. Amarsanaa Jazag (Mongolia)

HP1-3 10218

Clinical and Epidemiological Analysis of Liver Cancer Patients Under Primary Health Care Center Surveillance in Mongolia

Dr. Amarsanaa Jazag (Mongolia)

HP1-4 10012

Clinical Characteristics and Survival Outcomes of Hepatocellular Carcinoma at Dr. Moewardi Regional Tertiary Referral Hospital, Indonesia: A Retrospective Study

Dr. Triyanta Yuli Pramana (Indonesia)

PHP1-5 10179

Discrepancy between the Real Clinical Status of Patients with HCC and Expectations from HCC Surveillance: A Single Center Study

Dr. Jiwoong Jang (Korea)

Poster Group 15 HCC Poster Session 2

Moderator: Dr. Masatoshi Akamatsu (Japan)

HP2-1 10217

Combined Assessment of Ferritin, AFP, and PIVKA-II in the Diagnosis of Hepatocellular Carcinoma

Dr. Amarsanaa Jazag (Mongolia)

HP2-2 10054

Clinical Impact of the aMAP Risk Score and Hepatocellular Carcinoma on Outcomes after Rifaximin Therapy for Hepatic Encephalopathy

Dr. Satoshi Takakusagi (Japan)

HP2-3 10214

Hepatic Encephalopathy among HCC Patients Monitored for 2 Years, A-HOC Study

Dr. Amarsanaa Jazag (Mongolia)

HP2-4 10018

Current Status of Hypozincemia and Zinc Supplementation in Patients with Hepatocellular Carcinoma at Our Hospital

Dr. Takeharu Asano (Japan)

HP2-5 10200

A Case of Mucosa-associated Lymphoid Tissue Lymphoma of the Liver Recurred with the Subsequent Palatal Lesion

Dr. Ryutoku Kondo (Japan)

Poster Group 16 HCC Poster Session 3

Moderator: Dr. Takuma Teratani (Japan)

HP3-1 10113

Long-Term Clinical Course of Hepatocellular Carcinoma

Dr. Keisuke Hamamura (Japan)

HP3-2 10190

Systemic Therapy for Advanced Hepatocellular Carcinoma in a Single Center

Dr. Toru Arano (Japan)

HP3-3 10226

Treatment Modalities and Response Patterns in Hepatocellular Carcinoma: Real-World Data from a Turkish Cohort

Dr. Murat Kekilli (Turkey)

HP3-4 10224

Clinical and Etiologic Characteristics of Hepatocellular Carcinoma in a Turkish Cohort

Dr. Gulden Bilican(Turkey)

HP3-5 10180

Ectopic Retroperitoneal Hepatocellular Carcinoma Mimicking GIST with Portal Vein Tumour Thrombosis

Dr. Prabhath Dasanayaka (Sri Lanka)

APASL Oncology 2026 Tokyo Poster Session Program

DAY 2, April 3 (Friday) 2026

Poster Area “Gallery 1&2” B1F, “Event Space” B2F

15:00-16:30 **Poster Free Paper Sessions**

Poster Group 17 Radiology Poster Session 1

Moderator: Dr. Takamasa Ohki (Japan)

RP1-1 10024

Diversity of Imaging Features in Intrahepatic Mass-forming Cholangiocarcinoma Across Different Background Liver Conditions

Dr. Kazuto Kozaka (Japan)

RP1-2 10030

Clinical Feasibility of Automated Image-Based Registration-Supported Ultrasound-CT Fusion and Its Patient-Dependent Limitations

Dr. Ryo Yano (Japan)

RP1-3 10055

ADC Increase as a Biomarker of Tumor Shrinkage and PIVKA-II Decline after SBRT in Hepatocellular Carcinoma: A Prospective Study

Dr. Osamu Tanaka (Japan)

RP1-4 10086

Predictors of Compensatory Hepatic Hypertrophy following Carbon Ion Radiotherapy in Hepatocellular Carcinoma and its Association with Long-term Clinical Outcomes

Dr. Takeshi Hatanaka (Japan)

Poster Group 18 Radiology Poster Session 2

Moderator: Dr. Hideo Yoshida (Japan)

RP2-1 10009

The Roll of Cyber-knife Treatment on Advanced Hepatocellular Carcinoma

Dr. Takamasa Ohki (Japan)

RP2-2 10052

Efficacy and Safety of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in BCLC Stage A

Dr. Kodai Suzue (Japan)

RP2-3 10059

Stereotactic Body Radiation Therapy for Intrahepatic Lesions of Hepatocellular Carcinoma

Dr. Yasuki Niimura (Japan)

RP2-4 10085

Case Study of Advanced Hepatocellular Carcinoma Treated with Combined Radiation Therapy and Chemotherapy

Dr. Hideo Yoshida (Japan)

RP2-5 10114

Treatment Outcomes of B-RTO and Subsequent Changes in Hepatic Functional Reserve

Dr. Ryosuke Hayakawa (Japan)

Poster Group 19 Surgical Poster Session 1

Moderator: Dr. Keiji Sano (Japan)

SP1-1 10040

Evaluation of Stepwise Indocyanine Green Dosing for Hepatic Segment Visualization in a Mouse Model

Dr. Shuhei Kanda (Japan)

SP1-2 10082

Development of Ultra-Fine 3D Images of Intrahepatic Glissonian Structure

Dr. Kazuma Hasegawa (Japan)

SP1-3 10036

Routine Use of Intravenous Acetaminophen Safely Enhances Pain Control After Minimally Invasive Hepatectomies

Dr. Kei Furuya (Japan)

SP1-4 10048

A Predictive Nomogram for Postoperative Delirium after Hepatectomy for Hepatocellular Carcinoma: Development, Validation, and Clinical Utility Analysis

Dr. Shu Inagaki (Japan)

SP1-5 10034

Redox-Active Compound Accelerates Liver Regeneration and Attenuates Acute Injury in Mouse Models: Relevance to Liver Tumor Resection

Dr. Hyun Ae Woo (Korea)

Poster Group 20 Surgical Poster Session 2

Moderator: TBA

SP2-1 10072

Conversion Surgery for Hepatocellular Carcinoma following Multidisciplinary Treatment

Dr. Masayuki Honda (Japan)

SP2-2 10175

A Case of Conversion Surgery for a Huge Unresectable Hepatocellular Carcinoma with a Pathological Complete Response after Short-term Immune Checkpoint Inhibitor Therapy Ceased by Liver Dysfunction

Dr. Hiroe Toyoda (Japan)

SP2-3 10195

A Case of Advanced Hepatocellular Carcinoma Responded to Durvalumab Monotherapy, Leading to Conversion Surgery

Dr. Hiroto Ota (Japan)

SP2-4 10104

A Case of Retroperitoneal Metastasis of Hepatocellular Carcinoma Resected Laparoscopically

Dr. Tatsunori Nadaya (Japan)

SP2-5 10193

Multidisciplinary Management for Recurrence after Liver Resection for Hepatocellular Carcinoma

Dr. Osamu Aramaki (Japan)

Poster Group 21 Surgical Poster Session 3

Moderator: Dr. Takeaki Ishizawa (Japan)

SP3-1 10080

Characteristics of HCV-Related Hepatocellular Carcinoma Patients Achieving Long-Term Cancer-Free Survival after Repeated Hepatectomy in SVR Status

Dr. Yuji Iimuro (Japan)

SP3-2 10149

Cure by Liver Transplantation of HCV-related Decompensated Cirrhosis with Hepatocellular Carcinoma Developing 14 Years after IFN-induced SVR

Dr. Rintaro Hamazaki (Japan)

SP3-3 10206

ALPPS followed by Salvage LDLT for Recurrent HCC

Dr. Alp Atasoy (Turkey)

SP3-4 10215

Immunosuppressive Medication Non-adherence in Liver Transplantation Adult Recipients in Vietnam

Dr. Nguyen Thai Van Anh (Viet Nam)

SP3-5 10023

A Resected Case of Gallbladder Carcinoma Difficult to Differentiate from Metastatic Gastric Cancer to the Gallbladder

Dr. Kenji Hirano (Japan)

Poster Group 22 Local Therapy Poster Session

Moderator: Dr. Hitoshi Maruyama (Japan)

LTP-1 10155

Percutaneous Radiofrequency Ablation in Early-stage Hepatocellular Carcinoma

Dr. Shinpei Sato (Japan)

LTP-2 10035

EUS-Guided Ethanol Injection for Hepatocellular Carcinoma Inaccessible by Percutaneous Approach: A Successful Case of Local Tumor Control

Dr. Takuro Nishiwaki (Japan)

LTP-3 10037

Efficacy and Safety of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in the Caudate Lobe: A Comparative Study with Radiofrequency Ablation Authors

Dr. Yuki Tamura (Japan)

LTP-4 10181

A Propensity Score-Matched Comparison of Particle Therapy and Transarterial Chemoembolization for Hepatocellular Carcinoma

Dr. Tomoharu Yamanaka (Japan)

LTP-5 10068

Exploring the Efficacy of Systemic Inflammatory Markers in Predicting Outcomes Post Transarterial Chemoembolization (c TACE & deb TACE)

Dr. Rajata Prabhakar Pande (India)

LTP-6 10033

Objective Response, Survival, and Downstaging After Yttrium-90 Radioembolization in Intermediate and Advanced Hepatocellular Carcinoma

Chieh-Ling Yen (Taiwan)

LTP-7 10186

Widespread Peritoneal Seeding after Popping Phenomenon during Microwave Ablation for Hepatocellular Carcinoma: A Case Report

Takumi Yanai (Japan)

Poster Group 23 Systemic Therapy Poster Session 1

Moderator: Dr. Tatsuya Minami (Japan)

STP1-1 10014

Superiority of ICI-Based Regimens Over TKIs in Advanced HCC: A Systematic Review and Meta-Analysis

Dr. Chih-Ming Lin (Taiwan)

STP1-2 10088

Comparative Outcomes of Immunotherapy plus Transarterial Therapy versus Systemic Therapy Alone in Hepatocellular Carcinoma: A Systematic Review

Dr. Dewi Prasetyaningtyas (Indonesia)

STP1-3 10016

COVID-19 Pandemic's Impact on the Global Disease Burden of HBV-related Hepatocellular Carcinoma in the Elderly

Dr. Yuwei Wang (China)

STP1-4 10031

COVID-19 Pandemic did not Affect the Treatment Uptake of Immunotherapy as the Treatment for Advanced Hepatocellular Carcinoma (HCC)

Dr. Vicki wing-ki Hui (Hong Kong)

Poster Group 24 Systemic Therapy Poster Session 2

Moderator: Dr. Hiroyoshi Taniguchi (Japan)

STP2-1 10062

Early Clinical Outcomes of Nivolumab plus Ipilimumab Combination Therapy for Advanced Hepatocellular Carcinoma

Dr. Taro Watabe (Japan)

STP2-2 10189

Initial Experience with Nivolumab plus Ipilimumab for Unresectable Hepatocellular Carcinoma, Including Predictions of Efficacy and Safety

Dr. Hironao Okubo (Japan)

STP2-3 10105

Effects and Side Effects for Unresectable Hepatocellular Carcinoma Treated by Atezolizumab plus Bevacizumab

Dr. Masatoshi Akamatsu (Japan)

STP2-4 10156

Efficacy and Safety of Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma with Child-Pugh Class B: A Single-Center Study

Dr. Mayuko Kondo (Japan)

STP2-5 10092

Efficacy of Immunotherapy for Hepatocellular Carcinoma in the Elderly

Dr. Kojiro Kobayashi (Japan)

STP2-6 10211

Bevacizumab only Treatment Outcomes After Invasive Treatment of HCC Classified by Hepatitis Virus Type, Gender, and Age Group

Dr. Amarsanaa Jazag (Mongolia)

Poster Group 25 Systemic Therapy Poster Session 3

Moderator: Dr. Koji Uchino (Japan)

STP3-1 10166

A Pretreatment Serum Cytokine Score Predicts Response to First-line Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma

Dr. Kazuki Nagai (Japan)

STP3-2 10188

Predictive Factors for Response to Dual Immune Checkpoint Inhibitor Therapy in Advanced Hepatocellular Carcinoma

Dr. Yutaro Hori (Japan)

STP3-3 10061

Evaluation of Liver and Spleen Volume Changes during Systemic Therapy for Hepatocellular Carcinoma

Dr. Koji Uchino (Japan)

STP3-4 10112

Effects of Combination Therapy with Tremelimumab and Durvalumab on Skeletal Muscle Mass and Cardiac Function in Patients with Unresectable Hepatocellular Carcinoma

Dr. Hideki Nagumo (Japan)

STP3-5 10079

Intratumoral Vascular Lake Formation in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Lenvatinib

Dr. Takuma Kaneko (Japan)

Poster Group 26 Systemic Therapy Poster Session 4

Moderator: Dr. Jun Arai (Japan)

STP4-1 10110

Outcomes of Locoregional Therapy followed by Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Dr. Takeshi Okamoto (Japan)

STP4-2 10152

Continuing or Switching Systemic Therapy Combined with Locoregional Therapy Defines a Personalized Strategy for Oligoprogression in Hepatocellular Carcinoma: A Multicenter Retrospective Study

Dr. Hongli Yu (China)

STP4-3 10044

Clinical Outcomes of TACE/TAI Using Cisplatin Combined with Lenvatinib as Second-line Therapy After Failure or Intolerance to Immune Checkpoint Inhibitors

Dr. Masaki Yoshikawa (Japan)

STP4-4 10093

Two Cases of Unresectable Hepatocellular Carcinoma Treated with LEN-TACE for Local Control during Dual Immune Checkpoint Inhibitor Therapy

Dr. Yusuke Masuda (Japan)

STP4-5 10198

The Evaluation of Clinical Impact of Additional TACE to Lenvatinib for HCC Patients

Dr. Jun Arai (Japan)

STP4-6 10168

The Impact of Scheduled LEN-TACE on Tumor Microenvironment for BCLC-B HCC

Dr. Jun Arai (Japan)

STP4-7 10099

Lenvatinib plus Drug-eluting Bead Transarterial Chemoembolization for Large Hepatocellular Carcinoma beyond the up to 7 Criteria

Dr. Mariko Irizato (Japan)

Poster Group 27 Systemic Therapy Poster Session 5

Moderator: Dr. Masaya Sato (Japan)

STP5-1 10002

Toxicity Turned Tolerance: Hematologic Adverse Events Managed Successfully in Hepatocellular Carcinoma with VP4 Portal Vein Tumor Thrombus under Atezolizumab-bevacizumab: A Case Report from Vietnam

Dr. Phuong Thi Dinh (Viet Nam)

STP5-2 10170

Efficacy and Safety of Lenvatinib for Unresectable Hepatocellular Carcinoma in Patients with Severe Renal Impairment

Dr. Takashi Nishimura (Japan)

STP5-3 10084

A Super-Elderly Male with Multiple Hepatocellular Carcinoma Achieving Long-Term Survival by Repeated Percutaneous Ablation Combined with Lenvatinib

Dr. Maki Tobaru (Japan)

STP5-4 10129

Desired Outcome of the STRIDE Regimen in an Advanced HCC Patient with Multiple Poor Prognostic Factors Outside HIMALAYA Trial Criteria: A Case Report

Dr. Ngan Nguyen (Viet Nam)

STP5-5 10039

Successful Transcatheter Aortic Valve Implantation Enabling Continuation of Systemic Chemotherapy in a Patient with Hepatocellular Carcinoma and Severe Aortic Stenosis: A Case Report

Dr. Kaho Miyazaki (Japan)

Poster Group 28 Systemic Therapy Poster Session 6

Moderator: Dr. Tomoharu Yamada (Japan)

STP6-1 10050

Subconjunctival Hemorrhage and Corneal Graft Failure following Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma: A Case Report

Dr. Tomoharu Yamada (Japan)

STP6-2 10150

Progressive Multifocal Leukoencephalopathy During Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma: A Case Report

Dr. Tamami Abe (Japan)

STP6-3 10071

A Case of Hepatocellular Carcinoma with Rectal Fistula Induced by Lenvatinib in a Patient with Crohn's Disease

Dr. Shigeki Yano (Japan)

STP6-4 10164

Stepwise Immune Re-Sensitization Induced by Short-Term VEGF Inhibition Enhances Antitumor Efficacy of Repeated Durvalumab Re-Challenge in Advanced Hepatocellular Carcinoma: A Case Report

Dr. Teiji Kuzuya (Japan)

Poster Group 29 Systemic Therapy Poster Session 7

Moderator: Dr. Yoshinari Asaoka (Japan)

STP7-1 10000

Exceptional Long-term Survival with Low-dose FP Regimen Hepatic Arterial Infusion Chemotherapy after Immune and TKI Failure in Advanced Hepatocellular Carcinoma: A Case Report from Vietnam

Dr. Huy Van Nguyen (Viet Nam)

STP7-2 10153

Evaluation of the Efficacy of Sequential Therapy with New FP and Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Dr. Akihiro Deguchi (Japan)

STP7-3 10157

5-fluorouracil plus Cisplatin Versus Cisplatin in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Randomized Controlled Trial

Dr. Hidetoshi Nakagawa (Japan)

STP7-4 10043

Near-Complete Response to Nivolumab + Ipilimumab in HCC With IVC Invasion: An Exceptional Outcome Beyond Trial Eligibility

Dr. Naoki Takamura (Japan)

STP7-5 10194

Dramatic Complete Response to Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma with Massive Liver Involvement

Dr. Yutaka Yata (Japan)

STP7-6 10140

Selective Control of Pulmonary Metastases by Chemotherapy in Hepatitis C-related Hepatocellular Carcinoma: A Case Report

Dr. Yoshie Kadota (Japan)

STP7-7 10028

Dual Tumor Response to Sequential Immune Checkpoint Inhibitors in Synchronous HCC and ESCC: A Case Report

Dr. Kotaro Matsumoto (Japan)

Poster Group 30 Late Breaker Poster Session 1

Moderator: Dr. Yoshinari Asaoka (Japan)

LBP1-1 10245

Recurrence After Achieving a Drug-Free State Following Response to Systemic Therapy in Hepatocellular Carcinoma: A Retrospective Case Series

Dr. Takanobu Kanaya (Japan)

LBP1-2 10258

An Analysis of Progression Patterns After Response to Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma

Dr. Haruka Anzai (Japan)

LBP1-3 10270

Real-World Outcomes and Characteristics of Responders in Advanced Hepatocellular Carcinoma Treated with Durvalumab/Tremelimumab

Dr. Takuya Yonemoto (Japan)

LBP1-4 10238

Real-World Early Experience with Ipilimumab Plus Nivolumab (IPINIVO) for Advanced Hepatocellular Carcinoma

Dr. Wataru Ueno (Japan)

LBP1-5 10269

Lessons Learned from 1,716 Hepatobiliary Cancers: Real World Outcomes of Immune Checkpoint Inhibitor Therapy

Dr. Shinya Takaoka (Japan)

Poster Group 31 Late Breaker Poster Session 2

Moderator: Dr. Shinpei Sato (Japan)

LBP2-1 10234

Exploring the Value of Imaging Indicators in Predicting TACE Refractoriness in Hepatocellular Carcinoma Based on Contrast-Enhanced CT

Dr. Ying Lei (China)

LBP2-2 10233

Trans Arterial Chemoembolization Combined with Immunotherapy for BCLC Stage B Hepatocellular

Carcinoma: A Systematic Review and Meta-analysis

Dr. Andree Kurniawan (Indonesia)

LBP2-3 10252

Safety and Recurrence Patterns of Ablation After Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

Dr. Yasuyuki Komiyama (Japan)

LBP2-4 10243

Clinical Response of Brain Metastasis from Hepatocellular Carcinoma Treated with a Multimodal Approach Using Lenvatinib and Radiotherapy: A Case Report

Dr. Quang Vinh Dang (Viet Nam)

LBP2-5 10242

Hepatocellular Carcinoma with Submandibular and Sternal Manubrial Metastases: Tumor Growth Rate Based Dynamic Assessment and Regorafenib Combined with a Tonifying Eliminating Harmonizing Strategy

Dr. Huijie Li (China)

LBP2-6 10271

Triple Trouble: A Case of Hepatocellular Carcinoma in a Patient with Previous Renal and Colonic Malignancies

Dr. Cleo Christille Lynn G. Lom-oc (Philippines)

Poster Group 32 Late Breaker Poster Session 3

Moderator: Dr. Tomoharu Yamada (Japan)

LBP3-1 10251

A CT-Based Hybrid Model for Predicting CK19-Positive Hepatocellular Carcinoma and Assessing Prognosis: A Multicenter Study

Dr. Yawen Wang (China)

LBP3-2 10263

Development of a Novel Erythrocyte-Related Risk Score for Prognosis Prediction in Hepatocellular Carcinoma Patients

Dr. Huiwen Yan (China)

LBP3-3 10262

Anemia Predicts Poor Prognosis in HBV-Related Hepatocellular Carcinoma: a Large-Scale Retrospective Study

Dr. Huiwen Yan (China)

LBP3-4 10253

Assessment of Liver Fibrosis Severity in Patients Infected with Hepatitis B and C Viruses

Dr. Dolgormaa Batsaikhan (Mongolia)

LBP3-5 10227

Level of IL-6 is Directly Correlated with the Severity of Hepatitis B

Dr. Mohamed Shafi Mahboob Ali (Malaysia)

Poster Group 33 Late Breaker Poster Session 4

Moderator: Dr. Shuntaro Obi (Japan)

LBP4-1 10244

The Mongolian and the Southeast Asian Cluster: Mapping the 2022 Liver Cancer Epidemic Across Asia

Dr. Ulil Albab Habibah (Indonesia)

LBP4-2 10264

Temporal Trends in Hepatocellular Carcinoma Mortality in a Historically High-Risk Region of Japan: A Population-Based Study from Yamanashi Prefecture

Dr. Hiroyuki Amano (Japan)

LBP4-3 10256

Long-term Trends in Incidence, Stage, and Survival of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Prospective Cancer Registry Analysis from 2006 to 2024

Dr. Shuntaro Obi (Japan)

LBP4-4 10266

Increasing Proportion but Stable Incidence of Non-B Non-C Hepatocellular Carcinoma in the Post-DAA Era: A Real-World Cohort Study

Dr. Hiroyuki Amano (Japan)

LBP4-5 10265

Efforts to Combat Hepatitis C in a Leading High-Prevalence Prefecture in Eastern Japan

Dr. Hiroyuki Amano (Japan)

LBP4-6 10229

Advancing Toward WHO's HCV Zero Goals: Performance Evaluation of the Elecsys HCV Duo for Simultaneous Antibody and Core Antigen Detection

Dr. Yosuke Hirotsu (Japan)

LBP4-7 10249

Identification of Patients with Positive Hepatitis Virus Markers by Hepatitis Medical Care

Coordinators

Dr. Keiji Kaneko (Japan)

Poster Group 34 Late Breaker Poster Session 5

Moderator: Dr. Naoto Fujiwara (Japan)

LBP5-1 10257

Single-Cell Profiling Reveals Novel Insights into Vessel Co-Option in Human Colorectal Liver Metastases

Dr. Lolita Dokshokova (Denmark)

LBP5-2 10259

Unbiased Single-Cell Transcriptome-Proteome Co-Profiling Reveals Post-Transcriptional Buffering in Rare CSF-CTCs

Dr. Liyong He (China)

LBP5-3 10268

Research on Targeted TGF-beta Pathway Inhibitors in Hepatocellular Carcinoma

Dr. Liang Shi (China)

LBP5-4 10267

Research on Targeted FGFR4 Inhibitors in Hepatocellular Carcinoma

Dr. Yuting Chen (China)

Poster Group 35 Late Breaker Poster Session 6

Moderator: Dr. Kenichi Ikejima (Japan)

LBP6-1 10237

Development of a Novel Flavonoid Derivative with a Potent Anti-steatosis Activity in HepG2 Cells for Therapeutic Use in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)

Dr. Jaslan Densumite (Thailand)

LBP6-2 10247

A Systematic Evaluation of Network Pharmacology Approaches for Elucidating Mechanisms and Therapeutic Effects of Herbal Medicines

Dr. Won-Yung Lee (Korea)

LBP6-3 10255

The Mechanism of Compound Kushen Injection in Regulating Phosphatidylcholine-Mediated NK Cell Suppression of Liver Cancer Ascites

Dr. Hao Liu (China)

PLBP6-4 10261

Efficacy of Yangyin Fuzheng Jiedu Prescription for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: An Evaluation Using Five Propensity Score Methods

Dr. Wanxin Shi (China)

LBP6-5 10260

Yangyin Fuzheng Jiedu Prescription Improves Survival in HBV Related Hepatocellular Carcinoma Patients with Anemia: A Promising Herbal Formula Under Translation

Dr. Wanxin Shi (China)